Healthcare
QSAM
Coming October 18, 2023
QSAM Biosciences is developing next-generation nuclear medicines for the treatment of cancer and other diseases.
Menu
QSAM Biosciences is developing next-generation nuclear medicines for the treatment of cancer and other diseases.
MAIA Biotechnology received preliminary data from its Phase 2 Clinical trial and the results are very promising.
Ispire is not a cannabis company. It is a technology company that makes hardware for cannabis consumers.
All-natural energy drink is catching the eye of top pros as they look for healthier alternatives to Red Bull and other energy drinks.
Gain is ready to move into a Phase 1 clinical trials for with a novel small-molecule treatment for Parkinson’s disease.
Kineta, Inc. (Nasdaq: KA), announced today the achievement of a development milestone which triggers a $5 million payment from its research and development collaboration with Merck
Sonim is following a trail blazed Range Rover, Yeti, and other brands from to turn their rugged heritage into a premium experience.
MAIA and Regeneron are evaluating THIO with Libtayo in a Phase 2 clinical trial for Non-Small Cell Lung Cancer.
Global Bioenergies is one of a handful of companies producing Sustanable Aviation Fuel certified by by ASTM International
How Kineta’s partnership with Merck could alter the future of cancer therapy by solving the challenge immuno-suppression
1460 Broadway
New York, NY 10036
(917) 747-6198
© Copyright 2021 FORCE Family Office